FTSE 100 chemicals business Croda International (LSE:CRDA) has been increasing its dividend annually for each of the last 32 years. And I think there’s more to come. The company’s share price is lower than it was five years ago, but I think the long-term prospects for the business look good. To me, this looks like a stock to buy while it’s on sale. Just under 90% of Croda’s revenue comes from two industries. The first is consumer care (52%) and the second is life sciences (36%). In consumer care, the company makes the chemicals that give things like skincare products their specific properties. So this might be reducing the appearance of wrinkles, or improving skin tone. In life sciences, Croda’s chemicals go into drug delivery systems. In short, this is what enables drugs – including Pfizer’s Covid-19 vaccine – to target specific parts of the body. Importantly, the dividend aristocrat isn’t a manufacturer of generic chemicals – its products are highly specialised. In my view, this makes it a much more attractive business to consider investing in. Generic chemicals companies sell their products at whatever the market rate is. The only kind of competitive advantage comes from keeping its own...